• In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z).
• This setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a concentrated late-stage pipeline.
• We’ll now examine how the FDA’s clinical hold on the MAGNITUDE program reshapes Intellia’s investment narrative and risk-reward profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.

Intellia Therapeutics Investment Narrative Recap

To own Intellia today, you have to believe that in vivo CRISPR can translate into viable, one-time treatments despite complex safety and regulatory hurdles. The FDA’s clinical hold on the MAGNITUDE ATTR program brings that trade-off into sharp focus, placing nex-z’s path forward as the key near term catalyst and the main company specific risk at the same time.

Against this backdrop, Intellia’s update that the Phase 3 lonvo-z trial in hereditary angioedema is fully enrolled, with data expected by mid 2026, stands out as the most relevant offsetting catalyst. If lonvo-z reads out favorably and progresses as planned, it could partially rebalance the company’s dependence on nex-z while investors wait for clarity on the MAGNITUDE holds.

Yet, in contrast to the long term CRISPR promise, investors should be aware that Intellia’s concentration in a few late stage programs means...

Intellia Therapeutics’ narrative projects $648.6 million revenue and $104.2 million earnings by 2028.

Uncover how Intellia Therapeutics' forecasts yield a $22.27 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community span about US$16.90 to US$234.57 per share, showing wide disagreement on upside. When you weigh these against the FDA clinical hold on MAGNITUDE, it is clear that views on Intellia’s future performance can diverge sharply and are worth comparing side by side.

Explore 7 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!

Build Your Own Intellia Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.